Author

E. B. Mokhtari

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Research Focus:benchmarking· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

A. R. Henry· 2 shared P. Mudvari· 2 shared A. Anderson· 1 shared A. Creanga· 1 shared A. Derrien-Colemyn· 1 shared A. Ganesh· 1 shared A. Hajduczki· 1 shared A. Pegu· 1 shared

Activity by Year

2021-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. R. Henry

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A SARS-CoV-2 spike ferritin nanoparticle vaccine protects against heterologous challenge with B.1.1.7 and B.1.351 virus variants in Syrian golden hamsters

K. M. Wuertz, E. Barkei, W.-h. Chen, E. J. Martinez, I. E. Naouar, L. Jagodzinski, D. Paquin-Proulx, G. D. Gromowski, I. Swafford, A. Ganesh, M. Dong, X. Zeng, P. V. Thomas, R. S. Sankhala, A. Hajduczki, , Vasan

This study evaluates a SARS-CoV-2 spike ferritin nanoparticle vaccine's effectiveness against B.1.1.7 and B.1.351 variants in hamsters, showing protection against disease and viral replication.

bioRxiv · Jun 16, 2021 · PreprintImmunology

Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant

V.-V. Edara, L. Lai, M. Sahoo, K. Floyd, M. Sibai, D. Solis, M. W. Flowers, L. Hussaini, C. R. Ciric, S. Bechnack, K. Stephens, E. B. Mokhtari, P. Mudvari, A. Creanga, A. Pegu, , M. Suthar

This study assesses neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant in convalescent and vaccinated individuals, finding it is 6.8-fold more resistant but still neutralizable.

bioRxiv · May 9, 2021 · PreprintImmunology